Danaher Corporation $DHR Stock Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its position in shares of Danaher Corporation (NYSE:DHR) by 0.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,671,318 shares of the conglomerate’s stock after selling 6,074 shares during the quarter. Danaher comprises about 3.5% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 7th largest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Danaher were worth $370,281,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Danaher during the second quarter worth $10,492,520,000. Wellington Management Group LLP grew its holdings in shares of Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the period. Jupiter Topco LLC purchased a new position in shares of Danaher during the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher during the 2nd quarter worth about $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher in the second quarter valued at about $993,846,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR opened at $230.36 on Monday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm’s 50 day moving average price is $216.32 and its 200 day moving average price is $197.39. The company has a market cap of $162.07 billion, a P/E ratio of 37.70, a PEG ratio of 2.89 and a beta of 0.76. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same period in the prior year, the business earned $1.89 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. On average, research analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 26.19%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. TD Cowen increased their target price on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday. Stifel Nicolaus upped their price objective on shares of Danaher from $220.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday. Barclays lifted their target price on shares of Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday. Wells Fargo & Company cut their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Finally, Guggenheim upped their price target on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $242.91.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.